Holen Sie sich die Stockscreener-App
8.99
5.52%
0.47
Schlusskurs vom Vortag:
$8.52
Offen:
$8.62
24-Stunden-Volumen:
3.69M
Relative Volume:
0.48
Marktkapitalisierung:
$1.04B
Einnahmen:
$52.86M
Nettoeinkommen (Verlust:
$-480.19M
KGV:
-1.9169
EPS:
-4.6899
Netto-Cashflow:
$-421.82M
1W Leistung:
+9.50%
1M Leistung:
-35.60%
6M Leistung:
-6.94%
1J Leistung:
-40.89%
1-Tages-Spanne:
$8.53
$9.10
1-Wochen-Bereich:
$8.135
$9.10
52-Wochen-Spanne:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.99 | 986.87M | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Pullback Watch: Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Weekly Recap & Intraday High Probability Alerts - moha.gov.vn
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Zacks Investment Research
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Will Intellia Therapeutics Inc. stock remain a Wall Street favorite2025 Geopolitical Influence & Accurate Intraday Trading Signals - moha.gov.vn
Operating cash flow per share of Intellia Therapeutics, Inc. – LSX:A2AG6H - TradingView
Is Intellia Therapeutics Inc 38I a good long term investmentDividend Yield Trends & These Picks Are Just One Breakout Away - earlytimes.in
5 Stocks with the Largest Fair Value Estimate Cuts After Q3 Earnings - Morningstar
Intellia Therapeutics Shares: A Crisis Crossroads - Ad-hoc-news.de
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - Insider Monkey
9 Oversold Biotech Stocks to Invest In - Insider Monkey
NTLA Stockholders Have Opportunity to Lead Intellia Therapeutics - The National Law Review
Intellia Therapeutics, Inc. Sued for Securities Law Violations – - The National Law Review
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Finviz
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Remind - The National Law Review
Is Intellia Therapeutics Attractive After a 70.6% Drop and Latest Clinical Trial Update? - Yahoo Finance
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Will Intellia Therapeutics Inc. (38I) stock outperform value peersEntry Point & AI Forecasted Entry/Exit Points - newser.com
What technical models suggest about Intellia Therapeutics Inc.’s comebackWeekly Trend Summary & AI Powered Market Trend Analysis - newser.com
How Intellia Therapeutics Inc. stock reacts to oil pricesJuly 2025 Earnings & Trade Opportunity Analysis Reports - newser.com
Can Intellia Therapeutics Inc. stock deliver surprise earnings beatMarket Movers & Free Real-Time Volume Trigger Notifications - newser.com
Can volume confirm reversal in Intellia Therapeutics Inc.2025 Price Targets & Long Hold Capital Preservation Tips - newser.com
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Intellia Therapeutics: A Worst-Case Risk Becomes A Tragic Reality (Downgrade) - Seeking Alpha
Why Intellia Therapeutics Inc. (38I) stock remains top ratedJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Intellia Therapeutics (NTLA): Exploring Valuation as Investors Digest Latest Quarterly Update - Sahm
Is Intellia Therapeutics Inc. still worth holding after the dipJuly 2025 Update & Community Supported Trade Ideas - newser.com
Can Intellia Therapeutics Inc. stock deliver strong Q4 earnings2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Intellia Therapeutics Faces Weak Start with 10.21% Gap Down Amid Market Concerns - Markets Mojo
What data driven models say about Intellia Therapeutics Inc.’s futureFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Insider Monkey
9 Best Gene-Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Intellia Therapeutics Shares Plunge on Clinical Trial Safety Concerns - AD HOC NEWS
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer |
Oct 01 '25 |
Sale |
17.38 |
1,871 |
32,518 |
55,266 |
| CHASE WILLIAM J | Director |
Aug 20 '25 |
Buy |
10.03 |
100,000 |
1,003,000 |
134,693 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
0.45%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):